William P Schiemann Selected Research

Transforming Growth Factor beta (TGF-beta)

7/2015	Tipping the balance between good and evil: aberrant 14-3-3ζ expression drives oncogenic TGF-β signaling in metastatic breast cancers.
1/2013	Sox4, EMT programs, and the metastatic progression of breast cancers: mastering the masters of EMT.
1/2011	Role of TGF-β and the tumor microenvironment during mammary tumorigenesis.
12/2010	Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth.
6/2010	The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells.
4/2010	PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis.
12/2009	p130Cas is required for mammary tumor growth and transforming growth factor-beta-mediated metastasis through regulation of Smad2/3 activity.
12/2009	Activated Abl kinase inhibits oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary tumors.
10/2009	Mechanisms of the epithelial-mesenchymal transition by TGF-beta.
9/2009	The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

William P Schiemann Research Topics

Disease

68	Neoplasms (Cancer) 02/2022 - 03/2004
40	Breast Neoplasms (Breast Cancer) 12/2021 - 01/2005
39	Neoplasm Metastasis (Metastasis) 01/2022 - 03/2004
19	Carcinogenesis 02/2022 - 01/2006
9	Triple Negative Breast Neoplasms 12/2021 - 11/2013
4	Carcinoma (Carcinomatosis) 11/2013 - 09/2009
3	Fibrosarcoma 03/2006 - 07/2002
2	Wounds and Injuries (Trauma) 01/2016 - 09/2004
2	Disease Progression 10/2009 - 08/2009
2	Inflammation (Inflammations) 03/2004 - 04/2002
1	T-Cell Lymphoma (Lymphoma, T Cell) 01/2022
1	Pathologic Complete Response 11/2017
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2016
1	Neoplasm Micrometastasis 08/2015

Drug/Important Bio-Agent (IBA)

27	Transforming Growth Factor beta (TGF-beta)IBA 07/2015 - 04/2002
13	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2017 - 01/2006
9	IntegrinsIBA 12/2021 - 01/2009
8	CarcinogensIBA 01/2014 - 03/2008
8	CytokinesIBA 01/2014 - 03/2004
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2013
6	Proteins (Proteins, Gene)FDA Link 11/2017 - 01/2009
6	Cytostatic AgentsIBA 06/2011 - 01/2006
6	p38 Mitogen-Activated Protein KinasesIBA 12/2009 - 03/2006
5	Long Noncoding RNAIBA 12/2021 - 10/2017
5	Phosphotransferases (Kinase)IBA 01/2016 - 03/2008
4	LigandsIBA 01/2019 - 08/2015
4	Peptides (Polypeptides)IBA 01/2019 - 01/2005
4	Fibronectins (Fibronectin)IBA 01/2018 - 07/2002
4	Biological ProductsIBA 01/2018 - 01/2011
4	Integrin beta3 (GPIIIa)IBA 08/2015 - 01/2006
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2014 - 08/2004
3	Telomerase (Telomerase Reverse Transcriptase)IBA 02/2022 - 12/2016
3	Epidermal Growth Factor (EGF)IBA 01/2022 - 06/2013
3	Protein Isoforms (Isoforms)IBA 01/2022 - 03/2014
3	Small Interfering RNA (siRNA)IBA 01/2019 - 01/2015
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2017 - 01/2011
3	ErbB Receptors (EGF Receptor)IBA 01/2016 - 06/2013
3	Cadherins (E-Cadherin)IBA 01/2016 - 07/2011
3	MicroRNAs (MicroRNA)IBA 01/2014 - 01/2013
3	Cystatin CIBA 08/2009 - 03/2004
2	LipidsIBA 01/2019 - 06/2015
2	gadofullereneIBA 01/2018 - 01/2017
2	Estrogen ReceptorsIBA 01/2017 - 03/2015
2	Matrix Metalloproteinases (MMPs)IBA 11/2016 - 01/2014
2	matrigelIBA 01/2016 - 03/2006
2	TOR Serine-Threonine KinasesIBA 01/2016 - 03/2015
2	Pharmaceutical PreparationsIBA 01/2016 - 01/2014
2	Protein-Lysine 6-Oxidase (Lysyl Oxidase)IBA 01/2015 - 05/2011
2	Transcription Factors (Transcription Factor)IBA 07/2011 - 12/2010
2	Transforming Growth Factor-beta Type I ReceptorIBA 12/2010 - 01/2004
2	Homeodomain Proteins (Proteins, Homeobox)IBA 12/2010 - 09/2009
2	AgarIBA 03/2010 - 08/2009
2	NF-kappa B (NF-kB)IBA 08/2009 - 03/2008
2	I-kappa B KinaseIBA 08/2009 - 03/2008
2	Transforming Growth Factor-beta Type II ReceptorIBA 04/2007 - 01/2005
2	Cysteine Proteinase InhibitorsIBA 01/2005 - 03/2004
2	CathepsinsIBA 01/2005 - 03/2004
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2022
1	Histones (Histone)IBA 01/2022
1	Histone Deacetylases (Histone Deacetylase)IBA 01/2022
1	Histone Deacetylase InhibitorsIBA 01/2022
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2019
1	cyclic arginine-glycine-aspartic acid peptideIBA 01/2019
1	NucleosidesIBA 01/2019
1	P-SelectinIBA 01/2018
1	taxaneIBA 11/2017
1	PlatinumIBA 11/2017
1	AnthracyclinesIBA 11/2017
1	Tumor Biomarkers (Tumor Markers)IBA 01/2017
1	Phenobarbital (Luminal)FDA Link 01/2017
1	Estrogens (Estrogen)FDA Link 01/2017
1	ChromatinIBA 01/2017
1	Contrast MediaIBA 01/2017
1	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 08/2016
1	VimentinIBA 01/2016
1	tyrosine receptor (receptor, tyrosine)IBA 01/2016
1	pertuzumabIBA 01/2016
1	human ERBB2 proteinIBA 01/2016
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2016
1	Mechanistic Target of Rapamycin Complex 2IBA 01/2016
1	Monoclonal AntibodiesIBA 01/2016
1	Radioisotopes (Radionuclides)IBA 08/2015
1	GoldIBA 08/2015
1	Parathyroid Hormone-Related ProteinIBA 07/2015
1	1-(2-(dodecyloxy)ethyl)pyrrolidine hydrochloride (DEP)IBA 03/2015
1	SurvivinIBA 03/2015
1	MitogensIBA 01/2015
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 03/2014
1	Activin Receptors (Activin Receptor)IBA 03/2014
1	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 03/2014
1	Metalloproteases (Metalloproteinases)IBA 01/2014
1	ThymidineIBA 12/2013
1	Cytotoxins (Cytolysins)IBA 11/2013

Therapy/Procedure

11	Therapeutics 02/2022 - 09/2004
9	Drug Therapy (Chemotherapy) 12/2021 - 05/2007
1	Neoadjuvant Therapy 01/2016
1	Intravenous Injections 06/2015
1	Molecular Targeted Therapy 01/2015
1	Radiotherapy 11/2013